Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to Pneumocystis murina infection in healthy mice

Clinical and Vaccine Immunology

Volumn 13, Issue 2, 2006, Pages 193-201

  Feola, David J ^a   Garvy, Beth A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COTRIMOXAZOLE; IMMUNOGLOBULIN G; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DRUG EXPOSURE; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTOXICITY; LUNG LAVAGE; LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PNEUMOCYSTIS; PNEUMOCYSTIS MURINA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; TRACHEOBRONCHIAL TREE;

ANIMALS; ANTIBODIES, FUNGAL; B-LYMPHOCYTES; BONE MARROW; DRUG INTERACTIONS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZIDOVUDINE;

EID: 33644881102     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.2.193-201.2006     Document Type: Article

References (74)

1. Ammann, A. J., G. Schiffman, D. Abrams, P. Volberding, J. Ziegler, and M. Conant. 1984. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA 251:1447-1449.
2. Ballet, J. J., G. Sulcebe, L. J. Couderc, F. Danon, C. Rabian, M. Lathrop, J. P. Clauvel, and M. Seligmann. 1987. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin. Exp. Immunol. 68:479-487.
3. Barile, M., D. Valenti, E. Quagliariello, and S. Passarella. 1998. Mitochondria as cell targets of AZT (zidovudine). Gen. Pharmacol. 31:531-538.
4. + lymphocytes. Chest 103:116S-118S.
5. Bernstein, L. J., H. D. Ochs, R. J. Wedgwood, and A. Rubinstein. 1985. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J. Pediatr. 107:352-357.
6. Bogliolo, G., R. Lerza, M. Mencoboni, A. Saviane, and I. Pannacciulli. 1988. Azidothymidine-induced depression of murine hemopoietic progenitor cells. Exp. Hematol. 16:938-940.
7. Boxenbaum, H., and C. DiLea. 1995. First-time-in-human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. 35:957-966.
8. Buhl, R., H. A. Jaffe, K. J. Holroyd, F. B. Wells, A. Mastrangeli, C. Saltini, A. M. Cantin, and R. G. Crystal. 1989. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet ii:1294-1298.
9. Carr, A., C. Swanson, R. Penny, and D. A. Cooper. 1993. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J. Infect. Dis. 167:180-185.
10. Carr, A., B. Tindall, R. Penny, and D. A. Cooper. 1993. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin. Exp. Immunol. 94:21-25.
11. Cote, H. C., Z. L. Brumme, K. J. Craib, C. S. Alexander, B. Wynhoven, L. Ting, H. Wong, M. Harris, P. R. Harrigan, M. V. O'Shaughnessy, and J. S. Montaner. 2002. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N. Engl. J. Med. 346:811-820.
12. Cribb, A. E., M. Miller, J. S. Leeder, J. Hill, and S. P. Spielberg. 1991. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab. Dispos. 19:900-906.
13. Cribb, A. E., and S. P. Spielberg. 1990. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab. Dispos. 18:784-787.
14. Crowe, S., D. A. Cooper, and D. E. Chambers. 1996. Managing HIV. Part 4. Primary therapy. 4.1. Antiretroviral therapies for HIV. Med. J. Aust. 164:290-295.
15. Cushion, M. T., J. J. Ruffolo, and P. D. Walzer. 1988. Analysis of the developmental stages of Pneumocystis carinii, in vitro. Lab. Investig. 58:324-331.
16. Dainiak, N., M. Worthington, M. A. Riordan, S. Kreczko, and L. Goldman. 1988. 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells. Br. J. Haematol. 69:299-304.
17. Dawood, M. R., B. Conway, P. Patenaude, F. Janmohamed, J. S. Montaner, M. V. O'Shaughnessy, and G. W. Hammond. 1998. Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. J. Clin. Immunol. 18:235-240.
18. Feola, D. J., and B. A. Garvy. 2005. Zidovudine plus sulfamethoxazole- trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice. Int. Immunopharmacol. 5:1881-1894.
19. Fischl, M. A. 1999. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 13(Suppl. 1):S49-S59.
20. Fischl, M. A., D. D. Richman, N. Hansen, A. C. Collier, J. T. Carey, M. F. Para, W. D. Hardy, R. Dolin, W. G. Powderly, J. D. Allan, et al. 1990. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann. Intern. Med. 112:727-737.
21. Foli, A., F. Benvenuto, G. Piccinini, A. Bareggi, A. Cossarizza, J. Lisziewicz, and F. Lori. 2001. Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS 15:1687-1694.
22. Freund, Y. R., L. Dousman, J. T. MacGregor, and N. Mohagheghpour. 2000. Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses. Toxicol. Sci. 55:335-342.
23. Furman, P. A., J. A. Fyfe, M. H. St Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
24. Garvy, B. A., and A. G. Harmsen. 1996. The role of T cells in infection-driven interstitial pneumonia after bone marrow transplantation in mice. Transplantation 62:517-525.
25. Garvy, B. A., and A. G. Harmsen. 1996. Susceptibility to Pneumocystis carinii infection: host responses of neonatal mice from immune or naive mothers and of immune or naive adults. Infect. Immun. 64:3987-3992.
26. Garvy, B. A., J. A. Wiley, F. Gigliotti, and A. G. Harmsen. 1997. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect. Immun. 65:5052-5056.
27. Gigliotti, F., B. A. Garvy, and A. G. Harmsen. 1996. Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. Infect. Immun. 64:1892-1899.
28. Gigliotti, F., and W. T. Hughes. 1988. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J. Clin. Investig. 81:1666-1668.
29. Gill, P. S., M. Rarick, R. K. Brynes, D. Causey, C. Loureiro, and A. M. Levine. 1987. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 107:502-505.
30. Gordin, F., C. Gibert, and M. E. Schmidt. 1994. Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. Am. J. Med. 96:94-95.
31. Gordin, F. M., G. L. Simon, C. B. Wofsy, and J. Mills. 1984. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 100:495-499.
32. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, A. Meibohm, J. H. Condra, F. T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E. A. Emini, J. A. Chodakewitz, R. Isaacs, and D. D. Richman. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133:35-39.
33. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173:1213-1225.
34. Harmsen, A. G., W. Chen, and F. Gigliotti. 1995. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect. Immun. 63:2391-2395.
35. + cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp. Med. 172:937-945.
36. Harmsen, A. G., and M. Stankiewicz. 1991. T cells are not sufficient for resistance to Pneumocystis carinii pneumonia in mice. J. Protozool. 38:44S-45S.
37. Hertzberg, R. C. 1989. Fitting a model to categorical response data with application to species extrapolation of toxicity. Health Phys. 57(Suppl. 1):405-409.
38. Janoff, E. N., J. M. Douglas, Jr., M. Gabriel, M. J. Blaser, A. J. Davidson, D. L. Cohn, and F. N. Judson. 1988. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J. Infect. Dis. 158:983-990.
39. Jones, J. L., D. L. Hanson, M. S. Dworkin, D. L. Alderton, P. L. Fleming, J. E. Kaplan, and J. Ward. 1999. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. Morb. Mortal. Wkly. Rep. CDC Surveill. Summ. 48:1-22.
40. Kaplan, J. E., H. Masur, and K. K. Holmes. 2002. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Morb. Mortal. Wkly. Rep. Recomm. Rep. 51:1-52.
41. Kovacs, J. A., J. W. Hiemenz, A. M. Macher, D. Stover, H. W. Murray, J. Shelhamer, H. C. Lane, C. Urmacher, C. Honig, D. L. Longo, et al. 1984. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann. Intern. Med. 100:663-671.
42. Lane, H. C., H. Masur, L. C. Edgar, G. Whalen, A. H. Rook, and A. S. Fauci. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
43. Lim, S. E., M. V. Ponamarev, M. J. Longley, and W. C. Copeland. 2003. Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J. Mol. Biol. 329:45-57.
44. Limper, A. H., J. S. Hoyte, and J. E. Standing. 1997. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J. Clin. Investig. 99:2110-2117.
45. Linton, P. J., J. Harbertson, and L. M. Bradley. 2000. A critical role for B cells in the development of memory CD4 cells. J. Immunol. 165:5558-5565.
46. Lund, F. E., K. Schuer, M. Hollifield, T. D. Randall, and B. A. Garvy. 2003. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J. Immunol. 171:1423-1430.
47. Macy, J. D., Jr., E. C. Weir, S. R. Compton, M. J. Shlomchik, and D. G. Brownstein. 2000. Dual infection with Pneumocystis carinii and Pasteurella pneumotropica in B cell-deficient mice: diagnosis and therapy. Comp. Med. 50:49-55.
48. Mahmood, I. 1996. Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area. Eur. J. Drug Metab. Pharmacokinet. 21:275-278.
49. Malaspina, A., S. Moir, S. Kottilil, C. W. Hallahan, L. A. Ehler, S. Liu, M. A. Planta, T. W. Chun, and A. S. Fauci. 2003. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J. Immunol. 170:5965-5972.
50. Marcotte, H., D. Levesque, K. Delanay, A. Bourgeault, R. de la Durantaye, S. Brochu, and M. C. Lavoie. 1996. Pneumocystis carinii infection in transgenic B cell-deficient mice. J. Infect. Dis. 173:1034-1037.
51. Martinez-Maza, O., E. Crabb, R. T. Mitsuyasu, J. L. Fahey, and J. V. Giorgi. 1987. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J. Immunol. 138:3720-3724.
52. McCune, J. M., R. Namikawa, C. C. Shih, L. Rabin, and H. Kaneshima. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:564-566.
53. McKallip, R. J., M. Nagarkatti, and P. S. Nagarkatti. 1995. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp120 of human immunodeficiency virus. Toxicol. Appl. Pharmacol. 131:53-62.
54. McKinney, R. E., Jr., M. A. Maha, E. M. Connor, J. Feinberg, G. B. Scott, M. Wulfsohn, K. McIntosh, W. Borkowsky, J. F. Modlin, P. Weintrub, et al. 1991. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N. Engl. J. Med. 324:1018-1025.
55. Mitsuyasu, R., J. Groopman, and P. Volberding. 1983. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. N. Engl. J. Med. 308:1535-1536.
56. Montaner, J. S., R. Hogg, J. Raboud, R. Harrigan, and M. O'Shaughnessy. 1998. Antiretroviral treatment in 1998. Lancet 352:1919-1922.
57. Morris, A., J. D. Lundgren, H. Masur, P. D. Walzer, D. L. Hanson, T. Frederick, L. Huang, C. B. Beard, and J. E. Kaplan. 2004. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10:1713-1720.
58. Naisbitt, D. J., J. Farrell, S. F. Gordon, J. L. Maggs, C. Burkhart, W. J. Pichler, M. Pirmohamed, and B. K. Park. 2002. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62:628-637.
59. Naisbitt, D. J., S. F. Gordon, M. Pirmohamed, C. Burkhart, A. E. Cribb, W. J. Pichler, and B. K. Park. 2001. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133:295-305.
60. Naisbitt, D. J., S. J. Hough, H. J. Gill, M. Pirmohamed, N. R. Kitteringham, and B. K. Park. 1999. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126:1393-1407.
61. Nolte, H., and H. Buttner. 1974. Investigations on plasma levels of sulfamethoxazole in man after single and chronic oral administration alone and in combination with trimethoprim. Chemotherapy 20:321-330.
62. Nolte, H., and H. Buttner. 1973. Pharmacokinetics of trimethoprim and its combination with sulfamethoxazole in man after single and chronic oral administration. Chemotherapy 18:274-284.
63. Paxton, J. W. 1995. The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs. Clin. Exp. Pharmacol. Physiol. 22:851-854.
64. Pirmohamed, M., A. M. Breckenridge, N. R. Kitteringham, and B. K. Park. 1998. Adverse drug reactions. BMJ 316:1295-1298.
65. Reilly, T. P., L. H. Lash, M. A. Doll, D. W. Hein, P. M. Woster, and C. K. Svensson. 2000. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Investig. Dermatol. 114:1164-1173.
66. Richman, D. D., M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, et al. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317:192-197.
67. Rieder, J., D. E. Schwartz, M. Fernex, T. Bergan, E. K. Brodwall, A. Blumberg, P. Cottier, and W. Scheitlin. 1974. Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot. Chemother. 18:148-198.
68. + T cells into severe combined immunodeficiency mice. J. Clin. Investig. 90:673-678.
69. Simberkoff, M. S., W. El Sadr, G. Schiffman, and J. J. Rahal, Jr. 1984. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Am. Rev. Respir. Dis. 130:1174-1176.
70. -/-) mice with Salmonella enterica serovar Typhimurium infection. Infect. Immun. 71:6808-6819.
71. van der Ven, A. J., P. P. Koopmans, T. B. Vree, and J. W. van der Meer. 1991. Adverse reactions to co-trimoxazole in HIV infection. Lancet 338:431-433.
72. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, Jr., R. C. Reichman, J. A. Bartlett, M. S. Hirsch, et al. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl. J. Med. 322:941-949.
73. Wolthers, K. C., S. A. Otto, S. M. Lens, R. A. Van Lier, F. Miedema, and L. Meyaard. 1997. Functional B cell abnormalities in HIV type 1 infection: role of CD40L and CD70. AIDS Res. Hum. Retrovir. 13:1023-1029.
74. + T cell-independent vaccination against Pneumocystis carinii in mice. J. Clin. Investig. 108:1469-1474.